According to the new market research report "Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025", published by MarketsandMarkets™, the Mycoplasma Testing Market is projected to reach USD 1,095 million by 2025 from USD 689 million in 2020, at a CAGR of 9.7%.
Browse in-depth TOC on "Mycoplasma
Testing Market"
111 – Tables
37 – Figures
154 – Pages
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=136509856
The global mycoplasma testing markets growth is
driven by factors such as the growing concerns over cell culture contamination,
growth in the pharmaceutical and biotechnology industries, and rising
pharmaceutical R & D activities and investments.
The assays, kits, & reagents products segment
accounted for the largest share of the mycoplasma testing market, by product
& service segment, in 2019
The mycoplasma testing market is segmented into
assays, kits, & reagents; instruments; and services based on product &
service. In 2019, the assays, kits, & reagents segment accounted for this
markets largest share. The frequent purchase of these consumables compared to
instruments and the increasing use of kit-based techniques for mycoplasma
testing are the essential factors driving this market segments growth.
Cell line testing segment to register the highest
growth rate during the forecast period
Based on application, the mycoplasma testing market
is segmented into cell line testing, virus testing, and end-of-production cell
testing. In 2019, the cell line testing segment accounted for the largest share
of this market. Factors such as the rapid growth in the biopharmaceutical
industry and the increasing demand for monoclonal antibodies drive this market
segments growth.
Get 10% Customization on this Research
Report: -https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136509856
North
America is the largest regional market for mycoplasma
testing market
The global mycoplasma testing market is segmented
into North America, Europe,
the Asia Pacific,
and the Rest of the World. In 2019, North
America accounted for the largest share of the global
mycoplasma testing market. The large share can be attributed primarily to the
growth in biotechnology and pharmaceutical industries, the high adoption rate
of novel technologies, and the large number of life science research studies
conducted in this region.
The major players operating in this market are
Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International,
Inc. (US), Lonza Group Ltd. (Switzerland),
Merck KGaA (Germany),
Roche Diagnostics (Switzerland),
American Type Culture Collection (US), Bionique Testing Laboratories, Inc.
(US), InvivoGen (US), PromoCell GmbH (Germany),
Biological Industries Israel Beit Haemek Ltd. (Israel),
Creative Bioarray (US), Mycoplasma Experience (UK), Norgen Biotek Corp. (Canada),
Agilent Technologies (US), Biotools B & M Labs, S.A. (Spain),
Eurofins Scientific (Luxembourg),
GeneCopoeia, Inc. (US), GenBio (Canada),
Minerva Biolabs GmbH (Germany),
Meridian Bioscience, Inc. (US), Sartorius AG (Germany),
Savyon Diagnostics (Israel),
Nelson Laboratories Fairfield, Inc. (US), Clongen Laboratories, LLC (US), and
ScienCell Research Laboratories, Inc. (Canada).
Browse Related Reports:
Blood Screening Market by
Technology (Nucleic Acid Amplification, (Real Time PCR), ELISA
(Chemiluminescence immunoassay), Rapid Test, Western Blot), Product
(Instrument, Reagent & Kits, Software) & End User (Blood Bank,
Hospital) - Global Forecast to 2025
https://www.marketsandmarkets.com/Market-Reports/blood-screening-market-267747042.html
In-Vitro Diagnostics
Market by Product & Service
(Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis),
Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases)
End User (Hospitals) - Global Forecast to 2025
https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html
No comments:
Post a Comment